You are here

  • Home
  • Archive
  • Volume 71, Issue 9
  • Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Article metrics

Article menu
Download PDFPDF
PostScript
Letter
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

 

Online download statistics by month:

Online download statistics by month: December 2021 to October 2024

AbstractFullPdf
Dec 202110071092356
Jan 2022592632179
Feb 202221724492
Mar 202220922969
Apr 202217519667
May 2022163185118
Jun 202215616653
Jul 202212314046
Aug 2022471470109
Sep 202221320689
Oct 202211810755
Nov 2022877927
Dec 2022877920
Jan 2023888332
Feb 2023726317
Mar 2023494521
Apr 202320356
May 202319842
Jun 202326933
Jul 202320155
Aug 202312532
Sep 202323153
Oct 202310844
Nov 202314744
Dec 202317767
Jan 2024291815
Feb 202453387
Mar 202418784
Apr 202431267
May 202416185
Jun 202418954
Jul 20248821
Aug 20246832
Sep 20247567
Oct 20247723
Total746741111441